Market Size of Non-invasive Ventilators Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Non-invasive Ventilators Market Analysis
The non-invasive ventilators (NIV) market is expected to register a CAGR of 5.9% over the forecast period.
The onset of the COVID-19 pandemic had a significant impact on the market studied. Due to the sudden onset of the pandemic, a short-term negative impact was initially seen on the market, owing to the decreased patient visits to hospitals and clinics. However, the market witnessed immense growth in the later phases of the pandemic due to increased demand for NIV for COVID-19 patients and other chronic respiratory disease patients. As per a research study published in the Clinical Respiratory Journal in March 2021, along with continuous positive airway pressure (CPAP), NIV was widely used to treat patients with moderate to severe acute respiratory failure (ARF). Also, the researchers concluded that when a group of patients with moderate to severe COVID-19 infection were studied, NIV was successful in 48% of the total studied population, and a 57% survival rate was seen among the patients in the intensive care unit (ICU) incubation after NIV. Thus, due to the high survival rate among the target patients, the demand for the NIVs increased. This significantly contributed to the market's growth and is further expected to continue its growth trend during the forecast period.
Factors such as increasing cases of respiratory disorders and a rapid increase in demand for non-invasive procedures are anticipated to fuel the market growth during the forecast period. In addition, advantages associated with various types of non-invasive (NIV) ventilators are other factors associated with the increasing adoption of the devices and garnering the market's growth.
Chronic respiratory diseases affect the airways and other parts of the lungs. Respiratory symptoms are among the major causes of consultation with doctors and physicians in primary healthcare centers. Some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). These patients require ventilation for a better outcome. According to an article published in NCBI in June 2022, non-invasive positive pressure ventilation delivers oxygen into the lungs via positive pressure without the need for endotracheal intubation and is used in both acute and chronic respiratory failure.
In addition, as per an article published in the LLICM in June 2022, in post-operative hypoxemia, NIV has been successfully used. In addition, facemask NIV is known to improve gas exchange, reduce breathing issues and improve clinical outcomes in patients with hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD), obesity-hypoventilation, and in patients with cardiogenic pulmonary edema. Thus, due to the associated benefits of the systems, the adoption of these devices is increasing and expected to fuel the growth of the market.
However, complications and side effects associated with ventilators, such as the risk of being affected with pneumonia, might lower the adoption of the products, hindering the market's growth.
